Phase 1b/2 trial of BI 836845, an insulin-like growth factor (IGF) ligand-neutralizing antibody, combined with exemestane (Ex) and everolimus (Ev) in hormone receptor-positive (HR plus ) locally advanced or metastatic breast cancer (BC): primary phase lb results
Cortes, J, Janez, NM, Sablin, MP, Perez-Fidalgo, JA, Neven, P, Hedayati, E, Ballester, A, Ehrhart, MP, Huang, DC, Bogenrieder, T, Schmid, P
Published in JOURNAL OF CLINICAL ONCOLOGY (2016)
Published in JOURNAL OF CLINICAL ONCOLOGY (2016)
Get full text
Conference Proceeding